Piotr Paluszek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Piotr Paluszek has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Adam Kobayashi
Department of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszyński University, 01-938 Warsaw, Poland
1 shared publication - Aleksandra Suchanek
American Heart of Poland, 32-500 Chrzanów, Poland
1 shared publication - Eugeniusz Hrycek
American Heart of Poland, Topolowa 16, 32-500 Chrzanów, Poland
1 shared publication - Jacek Bil
National Medical Institute of the Ministry of Interior and Administration, 02-507 Warsaw, Poland
1 shared publication - Mariola Sznapka
Faculty of Medicine, Upper Silesian Academy Wojciecha Korfantego, 40-659 Katowice, Poland
1 shared publication - Michał Nowakowski
Faculty of Medicine, University of Silesia, 40-055 Katowice, Poland
1 shared publication
Latest Publications
- Open Access
- 18 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (8) , 2814
Long-Term Performance and Safety of the Self-Expandable Carotid Stent MER: 5-Year Outcomes from the OCEANUS Study, with Subgroup Analysis Based on Predilatation Before Carotid Artery Stenting
Background: Carotid artery stenting (CAS) with neuroprotection is a widely used treatment for carotid artery stenosis. This study aimed to evaluate the long-term outcomes of CAS using the MER stent (Balton, Poland) and various neuroprotection devices, with subgroup analysis based on predilatation. Methods: A prospective analysis was conducted on patients treated with CAS at four high-volume centers in Poland between October 2016 and May 2017. Patients were stratified into two groups based on whether predilatation was performed. Procedural and clinical outcomes, including major adverse events (MAEs) defined as all-cause death, stroke, and myocardial infarction (MI), were evaluated at 30 days and 5 years post-procedure. Kaplan–Meier analysis and Cox regression models were used to assess event-free survival and predictors of MAEs. Results: The study population consisted of 100 patients (males: 61%) with a mean age of 68 years. Dyslipidemia (84.4% vs. 60.0%, p = 0.007) and smoking (67.3% vs. 44.4%, p = 0.022) differed significantly between the predilatation and non-predilatation groups. The procedural success rate (p = 0.03). Conclusions: CAS with the MER stent demonstrated high procedural success and favorable long-term outcomes. Predilatation did not impact outcomes. Neuroprotection was effective in all cases, with no device-related complications reported.
- 18 April 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (8) , 2814
Open AccessLong-Term Performance and Safety of the Self-Expandable Carotid Stent MER: 5-Year Outcomes from the OCEANUS Study, with Subgroup Analysis Based on Predilatation Before Carotid Artery Stenting
Background: Carotid artery stenting (CAS) with neuroprotection is a widely used treatment for carotid artery stenosis. This study aimed to evaluate the long-term outcomes of CAS using the MER stent (Balton, Poland) and various neuroprotection devices, with subgroup analysis based on predilatation. Methods: A prospective analysis was conducted on patients treated with CAS at four high-volume centers in Poland between October 2016 and May 2017. Patients were stratified into two groups based on whether predilatation was performed. Procedural and clinical outcomes, including major adverse events (MAEs) defined as all-cause death, stroke, and myocardial infarction (MI), were evaluated at 30 days and 5 years post-procedure. Kaplan–Meier analysis and Cox regression models were used to assess event-free survival and predictors of MAEs. Results: The study population consisted of 100 patients (males: 61%) with a mean age of 68 years. Dyslipidemia (84.4% vs. 60.0%, p = 0.007) and smoking (67.3% vs. 44.4%, p = 0.022) differed significantly between the predilatation and non-predilatation groups. The procedural success rate (p = 0.03). Conclusions: CAS with the MER stent demonstrated high procedural success and favorable long-term outcomes. Predilatation did not impact outcomes. Neuroprotection was effective in all cases, with no device-related complications reported.